Periproducts Limited has been acquired by Venture Life Group plc
The private shareholders of Periproducts Limited have sold the company to Venture Life Group plc for US$8 million.
Perirpoducts is an independent, privately owned British company that produces and markets the award-winning UltraDEX Performance Oral Care range. Over the last 20 years, the company has been recognized for its innovative oral care products, incorporating the latest ingredients and technology, and backed by scientific research.
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercializing products for the ageing population. The group’s product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin.
Oaklins Cavendish, based in the UK, advised the seller in this transaction.
Talk to the deal team
Related deals
Armira has signed an agreement to acquire a majority stake in Viabus
Armira, a Germany-based investment firm, has signed an agreement to acquire a majority stake in Viabus, a leading Dutch tour operator focused on senior and young senior travelers.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more